Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Guselkumab Immunogenetics (TIG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04645355
Recruitment Status : Recruiting
First Posted : November 27, 2020
Last Update Posted : April 21, 2021
Sponsor:
Collaborator:
Janssen Biotech, Inc.
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

Condition or disease Intervention/treatment Phase
Psoriasis Guttate Plaque Psoriasis Drug: Guselkumab Phase 4

Detailed Description:
Guselkumab (Tremfya®), an IL-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Given the potential role of IL-23 in the pathogenesis of guttate psoriasis, guselkumab may be an effective option to treat the initial manifestation of guttate psoriasis. This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab. The primary objective of this study is to assess how treatment with guselkumab changes the immune milieu of the skin in patients with plaque or guttate psoriasis. The secondary objectives of this study are to assess how treatment with guselkumab affects the quality of life and extent of skin disease in patients with plaque or guttate psoriasis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a single center, open-label study. Twenty-five subjects are planned (15 with new-onset guttate psoriasis and 10 with chronic plaque psoriasis). Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunogenetic Profiling of Guselkumab for the Treatment of Plaque and Guttate Psoriasis
Actual Study Start Date : March 1, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Guselkumab

Arm Intervention/treatment
Experimental: New-onset guttate psoriasis
Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
Drug: Guselkumab
All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44

Experimental: Chronic plaque psoriasis
Subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44. At week 44, patients who have not achieved PASI 50 (nonresponders) will be removed from the trial. Patients who achieve between PASI 50 and PASI 75 (partial responders) will continue on drug throughout the remainder of the study. Patients who achieve PASI 75 or greater at week 44 (responders) will have their guselkumab therapy withdrawn and re-treated upon relapse.
Drug: Guselkumab
All subjects will initially be treated with guselkumab 100 mg SQ at weeks 0, 4, and then every 8 weeks thereafter until week 44




Primary Outcome Measures :
  1. Lesional CD4+ T effector cells [ Time Frame: baseline and week 44 ]
    Mean change from baseline in percent of lesional CD4+ T effector cells producing IL-17

  2. Lesional CD8+ T effector cells [ Time Frame: baseline and week 44 ]
    Mean change from baseline in percent of lesional CD8+ T effector cells producing IL-17



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

For subjects with guttate psoriasis:

  • Ability to provide written informed consent and comply with the protocol.
  • At least 18 years of age.
  • Diagnosis of guttate psoriasis.
  • Onset of guttate psoriasis within 12 months.
  • Body surface area (BSA) involvement greater than or equal to 5%.
  • PASI greater than or equal to 4.
  • Subject is considered a candidate for phototherapy or systemic therapy.
  • Subject is unlikely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods). Women of childbearing potential will be allowed to enroll provided they practice adequate forms of birth control.
  • Physical exam with no evidence of active skin infection and/or other findings that indicate chronic disease or concomitant inflammatory/immune-mediated skin disease other than psoriasis.

For subjects with chronic plaque psoriasis (control):

  • Ability to provide written informed consent and comply with the protocol.
  • At least 18 years of age.
  • Diagnosis of plaque psoriasis.
  • Duration of plaque psoriasis >5 years.
  • Body surface area (BSA) involvement greater than or equal to 5%.
  • Subject is considered a candidate for phototherapy or systemic therapy.
  • Subject is unlikely to conceive due to male, post-menopausal, or using adequate contraceptive (barrier, hormonal, implant, or permanent sterilization methods). Women of childbearing potential will be allowed to enroll provided they practice adequate forms of birth control.
  • Physical exam with no evidence of active skin infection and/or other findings that indicate chronic disease or concomitant inflammatory/immune-mediated skin disease other than psoriasis.

Exclusion Criteria:

For subjects with guttate psoriasis:

  • Subject is unable to provide written informed consent or comply with the protocol.
  • Subject is younger than 18 years of age or older than 70 years.
  • Have a history of active, chronic or recurrent infectious disease including HIV, hepatitis B, or hepatitis C.
  • Have active tuberculosis or latent tuberculosis without at least 4 weeks of treatment with isoniazid.
  • Have current signs or symptoms of severe, progressive, or uncontrolled medical disease.
  • Known allergies, hypersensitivity, or intolerance to guselkumab (TremfyaTM) excipients.
  • Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
  • Have any known malignancy or have a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to screening)
  • Are pregnant, nursing, or planning a pregnancy while enrolled in the study or for 12 weeks after the study agent injection for women or are planning to father a child while enrolled in the study or for 12 weeks after the last study agent injection.
  • Are participating in another study using an investigational agent or procedure during participation in this study.
  • Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
  • Subjects possess other diagnoses that, in the investigator's opinion interfere with the evaluation of the subject's guttate psoriasis.
  • Pre-existing psoriasis of any type for longer than 6 months. (i.e. plaque, guttate, palmoplantar, pustular, erythrodermic)
  • Previous treatment for psoriasis with phototherapy (narrowband ultraviolet (UV) B, broadband UVB, or UVA), systemic agents (methotrexate, acitretin, cyclosporine, apremilast), or biologic agents (etancercept, adalimumab, ustekinumab, secukinumab, etc.)

For subjects with chronic plaque psoriasis:

  • Subject is unable to provide written informed consent or comply with the protocol.
  • Subject is younger than 18 years of age or older than 70 years.
  • Have a history of active, chronic or recurrent infectious disease, including HIV, hepatitis B, or hepatitis C.
  • Have active tuberculosis or latent tuberculosis without at least 4 weeks of treatment with isoniazid.
  • Have current signs or symptoms of severe, progressive, or uncontrolled medical disease.
  • Known allergies, hypersensitivity, or intolerance to guselkumab (TremfyaTM) excipients.
  • Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
  • Have any known malignancy or have a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to screening)
  • Are pregnant, nursing, or planning a pregnancy while enrolled in the study or for 12 weeks after the study agent injection for women or are planning to father a child while enrolled in the study or for 12 weeks after the last study agent injection.
  • Are participating in another study using an investigational agent or procedure during participation in this study.
  • Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements.
  • Subjects possess other diagnoses that, in the investigator's opinion, interfere with the evaluation of the subject's plaque psoriasis.
  • Prior history of guttate psoriasis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04645355


Contacts
Layout table for location contacts
Contact: Nicholas Brownstone, MD 415-476-3396 Nicholas.Brownstone@ucsf.edu

Locations
Layout table for location information
United States, California
UCSF Psoriasis and Skin Treatment Center Recruiting
San Francisco, California, United States, 94118
Contact: Nicholas Brownstone, MD    415-476-3396    nicholas.brownstone@ucsf.edu   
Principal Investigator: Wilson Liao, MD         
Sponsors and Collaborators
University of California, San Francisco
Janssen Biotech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Wilson Liao, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04645355    
Other Study ID Numbers: 20-32273
First Posted: November 27, 2020    Key Record Dates
Last Update Posted: April 21, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Non-identifying clinical and research data may be shared with Janssen Biotech, UCSF and FDA, as well as other qualified scientists upon publication and upon request

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases